Pharma Focus Asia

Repligen

LATEST NEWSRead more...

12

Jul 2024

Sanyou Bio and BioGeometry Join Forces to Develop AI-Powered Antibody Drug Discovery Platform

BioGeometry and Sanyou Bio have announced a strategic partnership to advance drug research and development BioGeometry known for its AIdriven protein design and Sanyou Bio a leader in innovative

12

Jul 2024

ADM Korea Launches First Clinical Trial of Niclosamide-Based Anticancer Drug for Prostate Cancer Patients Resistant to Hormone Therapy

ADM Korea a subsidiary of Hyundai Bioscience has announced plans to initiate clinical trials for their niclosamidebased oral metabolic anticancer drug targeting prostate cancer patients

11

Jul 2024

Leqembi Receives Approval for Treating Alzheimer's Disease in Hong Kong

BioArctic AB and Eisai have announced that Leqembi a treatment for Alzheimers disease has been approved by the Department of Health in Hong Kong This approval marks its fifth global approval following the US Japan China and South Korea

11

Jul 2024

Reviva Pharmaceuticals Receives European Patent for Brilaroxazine in Treating Pulmonary Hypertension

Reviva Pharmaceuticals Holdings Inc announced today that it has been granted European Patent EP by the European Patent Office for the use of brilaroxazine in treating pulmonary hypertension

10

Jul 2024

Interius BioTherapeutics Secures HREC Approval and TGA Clearance for Phase 1 Trial of First-of-its-Kind In Vivo CAR Therapy for B Cell Cancers

Interius BioTherapeutics a pioneering developer of in vivo cellspecific gene medicines has secured Human Research Ethics Committee approval and Clinical Trial Notification clearance

09

Jul 2024

Amarin Partner EddingPharm Secures Approval for VASCEPA® (Icosapent Ethyl) in Mainland China to Reduce Cardiovascular Risk

Amarin Corporation plc has announced that its partner in Mainland China EddingPharm has received regulatory approval from Chinas National Medical Products Administration

Solovpe

press releasesRead more...

12

Jul 2024

MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K Investigational Therapy, MTX-531, Demonstrates Significant Tolerability and Durable Tumor Regressions

MEKanistic Therapeutics Inc a biotechnology company pioneering the development of nextgeneration kinase inhibitors for cancer treatment

12

Jul 2024

First Patient Dosed in Phase I Clinical Trial of YOLT-201

YolTech Therapeutics a biotech company developing in vivo gene editing therapies to treat rare genetic diseases announced today the successful enrollment of the first patient in the Phase I clinical trial of YOLT its independently developed in vivo gene editing therapy

12

Jul 2024

Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc.

The National Cancer Center and The University of Pennsylvania have licensed patent rights directed to a chimeric antigen receptor T cell therapy that targets the chemokine receptor CCR

11

Jul 2024

Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

Monopar Therapeutics Inc a clinicalstage radiopharma company focused on developing innovative treatments for cancer patients today announced the enrollment of the first patient

11

Jul 2024

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma Inc a late clinicalstage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration today announced the completion

11

Jul 2024

Indegene Announces Strategic Collaboration with Microsoft to Help Life Sciences Companies Scale Up Generative AI Adoption and Accelerate Business Impact

Indegene today announced a strategic collaboration with Microsoft to empower global life sciences companies to scale up the adoption of purposebuilt enterprisegrade Generative AI services

30 - 01

Jul 2024

30 - 01

Jul 2024

chemical indonesia

jakarta barat, Indonesia

30 - 01

Jul 2024

Inalab 2023

Jakarta Barat, Indonesia

13 - 14

Aug 2024

ADVANCING BUSINESS, TECHNOLOGY AND INNOVATION

Songdo Convensia, Incheon, South Korea

13 - 14

Aug 2024

12 YEARS OF EXCELLENCE: SOUTH KOREA’S BIOLOGICS

Songdo Convensia, Incheon, South Korea

19 - 21

Aug 2024
Cytiva - Supor Prime filters
MFA + MMA 2024
4th Annual Cleaning Validation 2024
2nd Annual Pharma Impurity Conclave 2024
CPHI Korea 2024
World Orphan Drug Congress Europe 2024
Thermo Fisher - Drug Discovery and the impact of mAbs

TOP ARTICLES

  • 4

    Neoteric Solvents: A Paradigm Shift in Pharmaceutical Industrial Processes

    Abhinab Goswami

    Pursuing Ph.D., National Institute of Pharmaceutical Education and Research

    Datta Maroti Pawde

    Pursuing Ph.D., National Institute of Pharmaceutical Education and Research

    Syed Nazrin Ruhina Rahman

    Pursuing Ph.D., National Institute of Pharmaceutical Education and Research

    T Raja Sekharan

    Faculty Member, SB College of Pharmacy

    Tamilvanan Shunmugaperumal

    Associate Professor, National Institute of Pharmaceutical Education and Research

    USN Murty

    Director, National Institute of Pharmaceutical Education and Research

KNOWLEDGE BANK

  • Interviews

    European Lead Factory

    Head of European Screening Centre

    Ton Rijnders is the Head of Screening at the European Lead Factory He holds a PhD in molecular biology and has an extensive experience with drug discovery in pharma with increasing managerial and scientific responsibilities Since November Ton is the General Director of Oncode Institute and has been involved since the very beginning in European Lead Factory via the partner Lygature
  • Articles

    Repurposed Drugs against the Latest Variants of Concerns of SARS-CoV-2

    The severe acute respiratory syndrome coronavirus SARSCoV affected all areas of life and the economy by causing COVID and created alarming caution in the form of variants of concerns VoC The latest VoC that are of public health relevance are Alpha B Beta B Gamma P Delta B and Omicron B Due to the emerging spread of these VoCs several vaccines

EDITORIAL SECTION